Press Release
Global Pertuzumab Market Set to Surpass USD 5 Billion by 2032
Pune, December 5, 2025 – Global Data Route Analytics has released its latest market intelligence report titled "Pertuzumab Market Forecast 2020–2035: Global Growth Trends, Size, Share & Competitive Landscape Analysis". The report offers a comprehensive view of the market’s projected evolution, including a detailed analysis of segment trends, regional growth dynamics, and the competitive landscape.
For a free sample of the report, please contact us here
https://globaldatarouteanalytics.com/report/234/global-pertuzumab-market/download
Valued at approximately USD 3.31 billion in 2024, the global Pertuzumab market is anticipated to exceed USD 5.05 billion by 2032, expanding at a CAGR of around 5.35% between 2025 and 2032. This steady growth is fueled by the increasing prevalence of HER2-positive breast cancer, rising access to targeted biologic therapies, and continued advancements in oncology care infrastructure across developed and emerging economies.
Pertuzumab has emerged as a key player in combination therapy regimens for HER2-positive breast cancer—particularly in metastatic and early-stage scenarios. Innovation in subcutaneous formulations and improved diagnostic pipelines are enhancing clinical outcomes and adoption rates.
For any inquiry related to this report, please click here
https://globaldatarouteanalytics.com/report/234/global-pertuzumab-market/inquiry
The report segments the market as follows:
• By Indication: HER2-Positive Breast Cancer, Metastatic Breast Cancer, Early-Stage Breast Cancer, Others
• By Route of Administration: Intravenous, Subcutaneous
• By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
• By End User: Hospitals, Cancer Treatment Centers, Specialty Clinics, Academic & Research Institutes
• By Region: North America (U.S., Canada), Europe (Germany, UK, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of Asia-Pacific), Latin America (Brazil, Mexico, Rest of Latin America), Middle East & Africa (South Africa, Saudi Arabia, UAE, Rest of MEA)
For discounts related to this report, explore here
https://globaldatarouteanalytics.com/report/234/global-pertuzumab-market/discount
The competitive landscape highlights key players such as:
• F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
• Pfizer Inc.
• Mylan N.V. (Viatris Inc.)
• Biocon Biologics Ltd.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Celltrion, Inc.
• Samsung Bioepis Co., Ltd.
• Dr. Reddy’s Laboratories Ltd.
• STADA Arzneimittel AG
• Novartis AG
• Eli Lilly and Company
• Accord Healthcare
• Fresenius Kabi
This report provides strategic insights into pipeline developments, regional forecasts, pricing trends, and regulatory benchmarks. It is an essential resource for stakeholders seeking to understand evolving opportunities in the oncology biologics domain.
About the Company
Global Data Route Analytics is a market research and consulting firm that provides businesses with data analysis, market forecasts, and tailored reports across various industries. The company uses advanced data analysis techniques, proprietary data, and an expert team to help clients understand market trends, make informed decisions, and develop strategies. They focus on delivering customized solutions, competitive intelligence, and growth strategies to help businesses succeed in their respective markets.
Media Contact:
Srushti Tungar
Global Data Route Analytics
